APA (7th ed.) Citation

Flinn, I. W. (2018). The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. American Society of Hematology (ASH).

Chicago Style (17th ed.) Citation

Flinn, I. W. The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL. American Society of Hematology (ASH), 2018.

MLA (9th ed.) Citation

Flinn, I. W. The Phase 3 DUO Trial: Duvelisib Vs Ofatumumab in Relapsed and Refractory CLL/SLL. American Society of Hematology (ASH), 2018.